Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
97
resultados
Última actualización
22/01/2026 [07:16:00]
Resumen de: CN120826235A
Techniques for providing immunogenic compositions (e.g., vaccines) and methods of inducing an immune response in a subject in need thereof are provided.
Resumen de: US20260015620A1
Methods for making synthetic gene clusters are described.
Resumen de: US20260007731A1
The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.
Resumen de: AU2024277588A1
Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.
Resumen de: CN120677168A
The present invention relates to a non-viable bacterial cell in which an immunogenic polypeptide fused to an autotransporter comprising a transmembrane linker and a transporter domain is displayed on the surface of the cell, as well as to formulations comprising such non-viable cells. The formulations are useful as oral vaccines.
Resumen de: MX2025014302A
The invention relates to direct-fed microbials for use in <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i> inhibition in animals. More particularly, the invention relates to isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), CM1004 (NRRL No. B-67708), and MDG1607 (NRRL No. B-67666), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), and CM1004 (NRRL No. B-67708), and strains having all of the identifying characteristics of these strains, to treat plants having diseases caused by <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i>.<u> </u>
Resumen de: CN121248735A
本发明属于生物技术领域，具体涉及一种具有增强TLR5配体活性的鞭毛蛋白突变体及其应用。选择鼠伤寒沙门氏菌鞭毛蛋白一个氨基酸突变位点，通过定点突变技术，利用大肠杆菌系统表达重组蛋白，经体外实验验证显示出良好的生物学活性，与野生型鞭毛蛋白突变体相比，能够更好的激活TLR5配体活性，为增强鞭毛蛋白佐剂和疫苗活性提供了良好的基础。
Resumen de: CN121248736A
本发明属于生物技术领域，具体涉及一种能够增强人源TLR5结合亲和力的鼠伤寒沙门菌鞭毛蛋白及其应用。本发明通过筛选并确定鞭毛蛋白的关键氨基酸突变位点，采用定点突变技术在大肠杆菌系统中实现重组表达。经体外实验验证，该衍生物能够显著激活TLR5配体功能。本发明解决了现有鞭毛蛋白在激活人源TLR5活性方面效果有限的问题，为鞭毛蛋白在疫苗、免疫治疗剂以及放射防护剂领域的应用提供了新的技术方案和理论基础。
Resumen de: WO2026006835A1
Disclosed are engineered outer membrane proteins (OMPs) that comprise one or more extracellular loops from the Salmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.
Resumen de: CN121227763A
一种将猪霍乱沙门氏菌进行低内毒化改造的方法及其应用，它涉及疫苗领域，本发明通过基因工程技术对猪霍乱沙门氏菌弱毒株SC014的lipid A修饰，对猪霍乱沙门氏菌进行低内毒素化改造，成功构建了低内毒素的猪霍乱沙门氏菌突变体。改造后的猪霍乱沙门氏菌及其外膜囊泡在显著降低内毒素活性的同时，仍能有效激活免疫反应，实现了安全性与有效性的兼顾，为开发新型疫苗提供了新的思路和方法。
Resumen de: US2025387373A1
In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Resumen de: CN120712079A
The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.
Resumen de: WO2025255902A1
A primer and probe for detecting Salmonella pullorum, and a kit. The primer comprises SP-F and SP-R for detecting the target sequence of the Salmonella pullorum (SP) citE2 gene, and the probe is modified with a fluorescent reporter group and a fluorescent quenching group. By means of providing the primer pair of SP-F and SP-R, which pair specifically binds to the target sequence of the citE2 gene, and combining the primer pair with the probe, whic is used for specific recognition, the accurate and sensitive detection of Salmonella pullorum can be realized.
Resumen de: KR20250175381A
본 발명은 항암 물질인 아르기닌 디이미나아제 (arginine deiminase; ADI)를 발현하는 항종양 박테리아 균주 및 이의 용도에 관한 것으로, 본 발명에 따른 항암 물질 생산 시스템이 도입된 면역 활성능이 있는 살모넬라 균주는 우수한 면역 항암 효능을 나타내어, 기존 항암제와 함께 또는 독립적으로 암의 치료제로 사용될 수 있다.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Resumen de: US2025375435A1
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.
Resumen de: US2025377362A1
The invention provides analytical methods for identifying and quantifying complex glycoconjugate compositions, in particular for the analysis of a glycoconjugate in a sample comprising at least 4 glycoconjugates.
Resumen de: WO2025246011A1
Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: CN121015753A
The invention discloses a dark plum antidiarrheal compound preparation for treating chicken diarrhea and a preparation method thereof. The dark plum antidiarrheal compound preparation is prepared from the following active ingredients: dark plum, schisandra chinensis, radix isatidis and berberis poiretii schneid in a mass ratio of (8-12): (12-16): (12-16): (8-12). The fructus mume antidiarrheal compound preparation for treating chicken diarrhea is low in price, and the cost of the fructus mume antidiarrheal compound preparation is reduced by 50% or above compared with that of currently common Chinese pulsatilla root oral liquid, Chinese pulsatilla root powder, Sihuang antidiarrheal granules, Siwei herba andrographitis powder and other compounds, and even is reduced by 500% or above compared with that of the Chinese pulsatilla root oral liquid/powder. The traditional Chinese medicine composition can completely inhibit characteristic pathological changes of peritonitis, pericarditis, perihepatic inflammation and enteritis caused by pathogenic bacteria of escherichia coli and salmonella by 100%, the cure rate of bacterial diarrhea is 100%, disordered intestinal flora and damaged intestinal villi of infected chickens can be recovered, and the inflammatory response of the infected chickens is remarkably reduced.
Resumen de: CN121022764A
The invention relates to the technical field of biology, in particular to a bacteriophage vBSalPSE29, a bacteriophage vBSalPSE29 preparation and application of the bacteriophage vBSalPSE29 preparation. The invention provides a bacteriophage vBSalPSE29, and the preservation number of the bacteriophage vBSalPSE29 is CGMCC (China General Microbiological Culture Collection Center) No.46499. The bacteriophage vBSalPSE29 is According to the salmonella pullorum bacteriophage provided by the invention, through whole genome sequencing analysis, gene sequences related to lysogenic transformation, antibiotic resistance and virulence factors are not detected in the genome of the salmonella pullorum bacteriophage, so that the biological safety of the bacteriophage for drug development and sterilization product development is ensured from the molecular level, and potential biological risks are effectively avoided.
Resumen de: CN121023055A
The invention discloses an avian salmonella nucleic acid rapid detection method based on a RAA-CRISPR-Cas13a technology and a kit, and belongs to the technical field of biochemistry and molecular biology. On the basis of the designed RAA primer pair and crRNA, the avian salmonella nucleic acid detection based on an RAA-CRISPR-Cas13a enzyme molecular system is established, the system is high in specificity and sensitivity, rapid detection of avian salmonella can be achieved within 30 minutes, the detection sensitivity of a fluorescence method can reach 100 copies/microliter, and the detection sensitivity of a test paper method can reach 102 copies/microliter. In addition, according to the system, expensive test equipment does not need to be operated in a standard professional laboratory, and field detection of clinical samples can be achieved through the portable visual transverse flow test strip.
Resumen de: CN121015731A
The invention discloses an extraction method and application of guava functional components for preventing and treating piglet diarrhea. The extraction method comprises the following steps: performing vacuum drying on guava leaves at 45-60 DEG C, and crushing; mixing with an ethanol-water mixed solvent, and carrying out ultrasonic-assisted extraction; filtering the extracting solution, concentrating under reduced pressure, and freeze-drying to obtain the guava leaf extract; according to the scheme, comprehensive prevention and control of bacterial diarrhea are achieved, phenolic compounds in GE directly inhibit growth of ETEC and salmonella, compound enzymes make up the defect that piglet digestive enzymes are insufficient to reduce intestinal burden, and traditional Chinese medicine compounds enhance the intestinal convergence function; the natural plant extract, the traditional Chinese medicine compound and the food-grade enzyme preparation are taken as core components, so that the problems of drug resistance and residue of antibiotics are avoided; ultrasonic-assisted ethanol-water mixed solvent extraction is adopted, and a freeze drying technology is combined, so that the yield of phenolic compounds in GE is increased, the impurity content is reduced, and the raw material cost and the feed palatability influence are reduced.
Nº publicación: CN121015906A 28/11/2025
Solicitante:
CHONGQING ACADEMY OF SCIENCE & TECH
\u91CD\u5E86\u5E02\u79D1\u5B66\u6280\u672F\u7814\u7A76\u9662
Resumen de: CN121015906A
The invention relates to the technical field of nano-drug carriers, in particular to a preparation method and application of enzyme-responsive nano-vesicles with pillararene as a carrier, a compound 30 is used as a starting raw material and condensed with a compound 31 under the action of EEDQ to obtain a compound 32, the compound 32 is subjected to Fmoc protection removal through piperidine and diethyl ether precipitation to obtain a compound 33, and the compound 33 is subjected to enzyme-responsive reaction to obtain the enzyme-responsive nano-vesicles with pillararene as the carrier. A compound 33 and a compound 34 react in DMF to obtain a compound 35, the compound 35 is subjected to trifluoroacetic acid deprotection to obtain a compound 36, the compound 36 and a compound 37 react and are subjected to column chromatography separation to obtain a compound 38, the compound 38 and terminal alkyne pillar arene 11 are subjected to 1, 3-dipole addition under the catalysis of Cu I/TBTA to obtain a compound 39, acetyl protecting groups are removed through sodium methoxide to obtain MP5, MP5 is dissolved in deionized water containing 1% of DMSO, dialysis is performed after ultrasonic treatment, and the compound 38 is obtained. The MP5 nano vesicle solves the problem that common antibiotics cannot play a role in intracellular parasitic salmonella, so that infection is difficult to radically treat.
BOPI
Sede Electrónica
